Clinical Trial: Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors

U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07368153) titled 'Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors' on Jan. 09.

Brief Summary: This clinical study will evaluate the safety and tolerability of an IDO-1 inhibitor in patients receiving a kidney transplant. The study includes individuals who have not previously been infected with Epstein-Barr virus (EBV) and who receive a kidney from a donor with prior EBV infection.

Participants will receive the IDO-1 inhibitor or placebo in addition to standard medical care and will be monitored for side effects and other sa...